Creating new combination therapies for a type of kidney cancer
Official title: Developing novel polytherapies for Non-Clear Cell Renal Cell Carcinoma
Funded at Oregon Health & Science University · NIH-11047661 · Data updated 2026-11-12
This study is exploring new treatment options for people with Non-Clear Cell Renal Cell Carcinoma, a tough type of kidney cancer, by testing a mix of two drugs that could help stop the cancer from growing and surviving.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2027 |
| Funding year | 2025 |
| Award (this year) | $381,047 |
| NIH project number | 5R01CA250378-05 |
| Project ID | NIH-11047661 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with Non-Clear Cell Renal Cell Carcinoma who have limited treatment options.
✕Less likely to help
Patients with other types of kidney cancer or those who do not have Non-Clear Cell Renal Cell Carcinoma may not benefit from this research.
What this research studies
This research focuses on developing innovative combination therapies for Non-Clear Cell Renal Cell Carcinoma (NCCRCC), a type of kidney cancer that currently lacks approved treatments. The approach involves using a combination of JAK and AKT inhibitors to target critical signaling pathways that promote tumor growth. By analyzing how these treatments affect cancer cells and patient tumors, the researchers aim to understand and overcome the mechanisms that allow cancer cells to survive despite therapy. This could lead to more effective treatment options for patients suffering from this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could provide new, effective treatment options for patients with Non-Clear Cell Renal Cell Carcinoma, potentially improving survival rates.
How similar studies have gone: While this approach is innovative, previous studies have shown promise in targeting similar pathways in other cancers, suggesting potential for success.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Thomas, George Victor — Oregon Health & Science University
- Study coordinator: Thomas, George Victor
Related research
Other NIH-funded projects on the same topics.
-
Understanding how kidney cancer spreads to bone and how to fight it
A patient-focused look at how clear cell renal cell carcinoma spreads to bone and how new treatments might help people with advanced disease.
-
Improve precision medicine for kidney cancer in people of African descent
A research project will explore why kidney cancer affects people of African ancestry differently and how to use genomics to guide better treatments.
-
Engineering immunogenic cell death to boost melanoma and kidney cancer therapy
This grant supports research aimed at making melanoma and kidney cancer cells die in a way that triggers a stronger immune response in patients.
-
Prognostic test to predict metastasis in clear cell kidney cancer
A new 12-marker biomarker test for people with clear cell renal cell carcinoma may help doctors predict which patients are at higher risk of metastasis.
-
Defining metabolic targets in kidney cancer for new treatments
A cancer-focused project is exploring how kidney cancer uses metabolism so doctors can find new, targeted ways to treat it.
-
Targeting HIF2 in kidney cancer: a new approach for clear cell RCC
A kidney cancer research program tests whether blocking HIF2 can slow or stop tumors in people with clear cell renal cell carcinoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.